moxifloxacin has been researched along with razoxane in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (razoxane) | Trials (razoxane) | Recent Studies (post-2010) (razoxane) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 824 | 115 | 56 |
| Protein | Taxonomy | moxifloxacin (IC50) | razoxane (IC50) |
|---|---|---|---|
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.19 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bois, P; Dilly, S; Ducroq, J; Faivre, JF; Guilbot, S; Laemmel, E; Le Grand, M; Moha ou Maati, H; Pons-Himbert, C; Stücker, O | 1 |
1 other study(ies) available for moxifloxacin and razoxane
| Article | Year |
|---|---|
Dexrazoxane protects the heart from acute doxorubicin-induced QT prolongation: a key role for I(Ks).
Topics: Animals; Antibiotics, Antineoplastic; Aza Compounds; Cardiovascular Agents; Cell Line; Delayed Rectifier Potassium Channels; Dose-Response Relationship, Drug; Doxorubicin; Drug Evaluation, Preclinical; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Guinea Pigs; Humans; In Vitro Techniques; Inhibitory Concentration 50; Long QT Syndrome; Moxifloxacin; Quinolines; Razoxane | 2010 |